Analysts predict that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will announce earnings of ($0.40) per share for the current quarter, according to Zacks. Five analysts have made estimates for Syros Pharmaceuticals’ earnings. The highest EPS estimate is ($0.33) and the lowest is ($0.44). Syros Pharmaceuticals posted earnings per share of ($0.47) in the same quarter last year, which indicates a positive year-over-year growth rate of 14.9%. The business is scheduled to announce its next earnings results on Thursday, August 6th.
According to Zacks, analysts expect that Syros Pharmaceuticals will report full year earnings of ($1.62) per share for the current year, with EPS estimates ranging from ($1.73) to ($1.33). For the next financial year, analysts expect that the business will report earnings of ($1.80) per share, with EPS estimates ranging from ($2.14) to ($1.44). Zacks’ EPS calculations are an average based on a survey of research analysts that follow Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.06. The firm had revenue of $2.38 million for the quarter, compared to the consensus estimate of $1.72 million. Syros Pharmaceuticals had a negative net margin of 1,950.42% and a negative return on equity of 84.15%.
Shares of NASDAQ:SYRS traded up $0.64 on Wednesday, reaching $10.67. The company’s stock had a trading volume of 6,099 shares, compared to its average volume of 421,084. Syros Pharmaceuticals has a 52-week low of $4.26 and a 52-week high of $11.93. The company has a market cap of $475.18 million, a P/E ratio of -5.81 and a beta of 1.62. The company has a 50-day simple moving average of $9.52 and a 200 day simple moving average of $7.57. The company has a debt-to-equity ratio of 0.58, a quick ratio of 6.35 and a current ratio of 6.35.
In other news, Director Richard A. Young sold 23,960 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $8.75, for a total value of $209,650.00. Following the sale, the director now directly owns 371,141 shares of the company’s stock, valued at approximately $3,247,483.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Srinivas Akkaraju sold 54,972 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $11.15, for a total transaction of $612,937.80. The disclosure for this sale can be found here. Insiders sold a total of 141,865 shares of company stock worth $1,496,316 over the last ninety days. Insiders own 14.20% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in SYRS. Portolan Capital Management LLC boosted its holdings in Syros Pharmaceuticals by 56.8% during the first quarter. Portolan Capital Management LLC now owns 512,570 shares of the company’s stock worth $3,040,000 after buying an additional 185,723 shares in the last quarter. Invesco Ltd. purchased a new stake in Syros Pharmaceuticals during the first quarter worth $534,000. Jacobs Levy Equity Management Inc. purchased a new stake in Syros Pharmaceuticals during the fourth quarter worth $312,000. Los Angeles Capital Management & Equity Research Inc. boosted its holdings in Syros Pharmaceuticals by 318.2% during the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 46,842 shares of the company’s stock worth $278,000 after buying an additional 35,641 shares in the last quarter. Finally, Nuveen Asset Management LLC lifted its holdings in Syros Pharmaceuticals by 30.6% during the fourth quarter. Nuveen Asset Management LLC now owns 140,627 shares of the company’s stock valued at $972,000 after purchasing an additional 32,988 shares in the last quarter. 98.23% of the stock is currently owned by hedge funds and other institutional investors.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Read More: Moving Average (MA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.